Boehringer Ingelheim Animal Health expanded its telemedicine offerings today with the PetPro Tele+ platform to help veterinarians and pet owners care for animals at a time of social distancing and beyond.
The platform provides an all-in-one telemedicine solution that people can access online for immediate use. It allows mobile-to-mobile appointments between veterinarians and pet owners who are limiting personal interaction to prevent the spread of the virus that causes COVID-19.
“Now more than ever, we are committed to helping veterinary clinics and pet owners continue to care for animals during an unprecedented public health crisis,” said Randolph Legg, Head of the US Commercial Business for Boehringer Ingelheim Animal Health. “We designed the PetPro Tele+ platform for veterinarians and pet owners who want to get up and running with telemedicine within minutes.”
PetPro Tele+ is a standalone, telemedicine version of PetPro Connect, a digital ecosystem that Boehringer Ingelheim introduced in select US markets in 2019. In March, as social distancing decreased in-person clinic visits, Boehringer Ingelheim made PetPro Connect available at no cost to veterinarians around the US who need a solution that fully integrates with a practice management system.
PetPro Tele+ and PetPro Connect both let veterinarians and pet owners schedule appointments and communicate by video and chat. They both are free. One key difference is that since PetPro Tele+ does not require integration with a practice management system, people can start using it within minutes. It also lets pet owners share photos, videos and other info with a veterinarian before and/or during a virtual appointment.
PetPro Tele+ is innovating telemedicine by delivering relevant, helpful pet care and clinic-related content from premier industry partners. This includes important and timely COVID-19 information along with engaging tips for pet owners.
PetPro Tele+ is available in the United States at www.petproconnect.com/teleplus and soon will be available for download on your preferred mobile device. Boehringer Ingelheim plans to introduce it soon in several other countries.